Friday, April 23, 2021 7:54:41 PM
Lets put it this way. The Barchart website is great in the way it subdivides companies into sectors. The biomedical sector has 450 companies, or something like that. It is by far the largest stock market sector.
When it comes producing a novel drug that meets regulatory approval so it can be subscribed, the capital requirement is immense. You already understand this.
The other major pharma companies that developed viable vaccines spent goodness knows how many millions. It comes with the territory.
Pfizer and Astra Zeneca are already cash rich companies that didn't have to float more stock to finance the R&D.
Interesting that no major pharma bothered to particpate in a collaborative venture.
The company has floated stock going on almost a year now. I wonder who owns substantial amounts of the outstanding.
Biden is trying his best to be optimistic about getting folks vaccinated in the US. It is still an uphill climb.
Worldwide, this herd immunity obective is nowheres close to a statistical reality.
When it comes producing a novel drug that meets regulatory approval so it can be subscribed, the capital requirement is immense. You already understand this.
The other major pharma companies that developed viable vaccines spent goodness knows how many millions. It comes with the territory.
Pfizer and Astra Zeneca are already cash rich companies that didn't have to float more stock to finance the R&D.
Interesting that no major pharma bothered to particpate in a collaborative venture.
The company has floated stock going on almost a year now. I wonder who owns substantial amounts of the outstanding.
Biden is trying his best to be optimistic about getting folks vaccinated in the US. It is still an uphill climb.
Worldwide, this herd immunity obective is nowheres close to a statistical reality.
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent OCGN News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 08:31:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 08:30:23 PM
- Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes • GlobeNewswire Inc. • 05/14/2026 08:30:00 PM
- Ocugen to Participate in Upcoming May Scientific and Investor Conferences • GlobeNewswire Inc. • 05/13/2026 11:02:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:12:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 03:37:19 PM
- Ocugen Provides Business Update with First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/05/2026 12:32:54 PM
- Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes • GlobeNewswire Inc. • 05/05/2026 12:12:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:03:53 PM
- Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes • GlobeNewswire Inc. • 05/04/2026 08:01:51 PM
- Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results • GlobeNewswire Inc. • 04/29/2026 11:02:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 11:01:37 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/28/2026 11:01:16 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 11:00:34 AM
- Ocugen to Present at April 2026 Investor and Industry Conferences • GlobeNewswire Inc. • 04/23/2026 11:02:00 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 04/20/2026 09:18:21 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 08:56:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 01:26:46 AM
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease • GlobeNewswire Inc. • 04/01/2026 11:02:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 04:02:11 PM
- Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 03/24/2026 11:45:00 AM
- Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy • GlobeNewswire Inc. • 03/23/2026 11:02:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 12:00:18 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 02:27:38 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/04/2026 05:23:26 PM
